In this line of evidence, pathway screening also identifies the PI3K/AKT cascade as the major downstream signaling mechanism underlying the oncogenic effect of ChREBP in HCC initiation and development. The gene discussed is MLXIPL; the disease is hepatocellular carcinoma.